IP Library Patent Application 13276268
Patent Application
App. No. 13/276,268

PLACENTAL STEM CELL POPULATIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/276,268
Abstract

The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.

Claims (33)

1 . An isolated adherent placental stem cell that is:

CD200 + and HLA-G + ;

CD73 + , CD105 + , and CD200 + ;

CD200 + and OCT-4 + ;

CD73 + , CD105 + and HLA-G + ;

CD73 + and CD105 + and facilitates the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow the formation of an embryoid-like body; or

OCT-4 + and facilitates the formation of one or more embryoid-like bodies in a population of placental cells comprising the stem cell when said population is cultured under conditions that allow formation of embryoid-like bodies; or any combination thereof.

2 . The isolated stem cell of claim 1 , wherein said CD200 + , HLA-G + stem cell is CD34 − , CD38 − , CD45 − , CD73 + and CD105 + .

3 . The isolated stem cell of claim 1 , wherein said CD73 + , CD105 + , and CD200 + stem cell is CD34 − , CD38 − , CD45 − , and HLA-G + .

4 . The isolated stem cell of claim 1 , wherein said CD200 + , OCT-4 + stem cell is CD34 − , CD38 − , CD45 − , CD73 + , CD105 + and HLA-G + .

5 . The isolated stem cell of claim 1 , wherein said CD73 + , CD105 + and HLA-G + stem cell is CD34 − , CD45 − , OCT-4 + and CD200 + .

6 . The isolated stem cell of claim 1 , wherein said CD73 + and CD105 + stem cell that facilitates the formation of one or more embryoid-like bodies is OCT4 + , CD34 − , CD38 − and CD45 − .

7 . The isolated stem cell of claim 1 , wherein said OCT-4 + and which facilitates the formation of one or more embryoid-like bodies is CD73 + , CD105 + , CD200 + , CD34 − , CD38 − , and CD45 − .

8 . A population of isolated placental stem cells that is enriched for adherent placental stem cells that are:

CD200 + and HLA-G + ;

CD73 + , CD105 + , and CD200 + ;

CD200 + and OCT-4 + ;

CD73 + , CD105 + and HLA-G + ;

CD73 + and CD105 + and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow the formation of an embryoid-like body; or

OCT-4 + and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising the stem cell when said population is cultured under conditions that allow formation of embryoid-like bodies.

9 . The population of claim 8 , wherein said CD200 + , HLA-G + stem cells are CD34 − , CD38 − , CD45 − , CD73 + and CD105 + .

10 . The population of claim 8 , wherein said CD73 + , CD105 + , and CD200 + stem cells are CD34 − , CD38 − , CD45 − , and HLA-G + .

11 . The population of claim 8 , wherein said CD200 + , OCT-4 + stem cell is CD34 − , CD38 − , CD45 − , CD73 + , CD105 + and HLA-G + .

12 . The population of claim 8 , wherein said CD73 + , CD105 + and HLA-G + stem cells are CD34 − , CD45 − , OCT-4 + and CD200 + .

13 . The population of claim 8 , wherein said CD73 + and CD105 + stem cells that facilitate the formation of one or more embryoid-like bodies are OCT4 + , CD34 − , CD38 − and CD45 − .

14 . The population of claim 8 , wherein said OCT-4 + stem cells that facilitate the formation of one or more embryoid-like bodies are CD73 + , CD105 + , CD200 + , CD34 − , CD38 − , and CD45 − .

15 . The population of claim 8 , wherein said population has been expanded.

16 . The population of claim 8 , wherein said population has been passaged at least once.

17 . The population of claim 8 , wherein said population has been passaged at least three times.

18 . The population of claim 8 , wherein said population has been passaged at least five times.

19 . The population of claim 8 , wherein said population has been passaged at least ten times.

20 . The population of claim 8 , wherein said cells have been cryopreserved, and wherein said population is contained within a container.

21 .- 52 . (canceled)

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2011
From: EDINGER, JAMES; YE, QIAN; WANG, JIA-LUN; HARIRI, ROBERT J.
To: ANTHROGENESIS CORPORATION
Reel/Frame 027218/0054 →